Headquartered in Mumbai, India, Lupin Ltd today is an innovation led transnational pharmaceutical company producing a wide range of quality, affordable generic and branded formulations and Active Pharmaceutical Ingredients (API) for the developed and developing markets of the world.
Lupin first gained recognition when it became one of the world's largest manufacturers of Tuberculosis drugs. The Company today has significant market share in key markets in the Cardiovascular (prils and statins), Diabetology, Asthma, Pediatrics, CNS, GI, Anti-Infectives and NSAIDs therapy segments, not to mention global leadership positions in the Anti-TB and Cephalosporins segments.
The Company's research and development (R&D) endeavours have resulted in significant progress in its NCE program. The Company's foray into Advanced Drug Delivery Systems has resulted in the development of platform technologies that are being used to develop value-added generic pharmaceuticals. Lupin's world class manufacturing facilities, spread across India and Japan, have played a critical role in enabling the companies realize its global aspirations.
Lupin: On a high growth path
|1989||Joint venture (JV) in Thailand – Lupin Chemicals (Thailand) Ltd was established|
|2001||Became only Asian pharmaceutical company to receive USFDA approvals for its sterile cephalosporin facility|
|2007||Received ‘Best new manufacturer of the year’ award from Amerisource Bergen|
|2011||Entered into joint development agreement with Medicis Enter|
|2013||Inaugurated new plant at Nagpur|